NeuroSense Collaborates With Lonza To Identify Exosome-Based Biomarkers For Advance Neurodegenerative Disease Treatments And Diagnostics
NeuroSense Collaborates With Lonza To Identify Exosome-Based Biomarkers For Advance Neurodegenerative Disease Treatments And Diagnostics
NeuroSense 与 Lonza 合作识别基于外泌体的生物标志物，用于先进的神经退行性疾病治疗和诊断
- NeuroSense will leverage its extensive experience in biomarker utilization to advance early diagnosis and treatment in the neurodegeneration field
- Lonza to develop, optimize, and qualify a method utilizing Neuron-Derived Exosomes ("NDEs"), set to be integrated into the clinical development program of PrimeC by NeuroSense
- Lonza's Dev-on-Demand solution to enable NeuroSense to access Lonza's process development with rapid initiation, execution, and delivery of work
- NeuroSense将利用其在生物标志物利用方面的丰富经验来推进神经变性领域的早期诊断和治疗
- Lonza将开发、优化和鉴定一种利用神经元衍生外泌体（“NDE”）的方法，该方法将整合到NeuroSense的PrimeC临床开发计划中
- Lonza 的按需开发解决方案使 NeuroSense 能够通过快速启动、执行和交付工作来访问 Lonza 的流程开发